SPRINT-TB
  • Home
  • About
    • About Us
    • Annual Report
    • Scientific Advisory Board
    • Funders
  • Research
    • Theme 1: Target Discovery
    • Theme 2: Drug Development
    • Theme 3: Clinical Trials
    • Theme 4: Treatment Delivery
  • News
  • Events
    • Journal Club
    • Annual Symposium
  • Giving
  • Contact
    • Contact
    • Careers

TRUNCATE-TB Trial Steering Committee Holds Its Inaugural Meeting in Singapore

17/2/2015

0 Comments

 
PictureAttendees of TRUNCATE-TB TSC Inaugural Meeting. Back row: Dr. Qingshu Lu, Dr. Padmasayee Papineni, Prof. Guy Thwaites, Dr. Meera Gurumurthy, Dr. Gerry Davies, Prof. Andrew Nunn, Dato' Dr. Hj. Abdul Razak Muttalif, Dr. Patrick Phillips, Prof. Charles Gilks, Prof. Nick Paton, Prof. Shenjie Tang, Dr. Sushil Pandey. Front row: Suelyn Lau, Dr. Rovina Ruslami, Dr. Sabai Phyu.
The Trial Steering Committee (TSC) of TRUNCATE-TB clinical trial assembled to hold its inaugural meeting on February 11, 2015 at National University of Singapore (NUS), Singapore.

The meeting was attended by TSC members (Dr. Gerry Davies (UK), Prof. Charles Gilks (Australia), Prof. Guy Thwaites (UK/Vietnam), Dato’ Dr. Hj. Abdul Razak Muttalif (Malaysia), Dr. Sushil Pandey (Australia)), trial chief investigator Prof. Nick Paton (Singapore), MRC Clinical Trials Unit members Prof. Andrew Nunn (UK) and Dr. Patrick Phillips (UK), as well as other trial core members and collaborators. Trial sites were represented by Dr. Rovina Ruslami (Padjadjaran University, Indonesia) and Prof. Shenjie Tang (Beijing Chest Hospital, China).

The assembly discussed the trial protocol and drug regimens, data management and biostatistics, as well as trial logistics, organisation and community involvement matters.

TSC meetings will be held regularly until the completion of the trial in 2019.
--
TRUNCATE-TB (Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis) is a ground-breaking Phase 3 TB treatment regimen shortening trial, which will recruit over 1,000 patients in multiple Asian countries. The aim of this study is to determine whether a strategy of treating drug-sensitive TB for 2 months with novel combination regimens and re-treating relapses with a 6 month course of standard treatment will be non-inferior to the standard 6 month treatment / 6-month re-treatment approach.

The trial is sponsored by University College London (UCL) and funded by Medical Research Council (MRC)/Wellcome Trust/Department for International Development (DfID) (UK) and National Medical Research Council (NMRC) (Singapore). The trial will be managed by National University Singapore (NUS) and coordinated by Singapore Clinical Research Institute (SCRI).

TRUNCATE-TB is one of the key projects under SPRINT-TB's Theme 3.

0 Comments

    Archives

    September 2018
    December 2017
    March 2017
    December 2016
    September 2016
    March 2016
    February 2016
    December 2015
    November 2015
    October 2015
    September 2015
    July 2015
    May 2015
    April 2015
    March 2015
    February 2015
    November 2014
    October 2014
    September 2014
    July 2014

    Categories

    All

    RSS Feed

Picture
Home | About | Research | News | Events | Contact
Intranet
Terms & Conditions
Copyright © 2014-2017 SPRINT-TB. All Rights Reserved.